Clinical trials: Age Related Maculopathy
Age-related Macular Degeneration, Dementia
Words on the Brain: Can Reading Rehabilitation for Age-Related Vision Impairment Improve Cognitive Functioning?
Age-related vision impairment and dementia both become more prevalent with increasing age. Research into the mechanisms of these conditions has proposed that some of their causes (e.g., macular degeneration/glaucoma and…
- Conditions
- Age-related Macular Degeneration, Dementia, Low Vision, Low Vision Aids
- Trial name
- WOTB (NCT04276610)
- Testing
- Low Vision Reading Rehabilitation
- Where
- 2 sites in Canada
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Université de Montréal
Macular Degeneration
MSI-1256F (Squalamine Lactate) in Combination With Verteporfin in Patients With "Wet" Age-Related Macular Degeneration (AMD)
Age-Related Macular Degeneration (AMD) is a degenerative disease of the retina that causes a progressive loss of central vision. AMD is the leading cause of legal blindness among adults age 50 or older in the Western world.
- Trial name
- NCT00094120
- Testing
- MSI-1256F (Squalamine Lactate)
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Genaera Corporation
Age-related Macular Degeneration
Changes in Retinal Function After Intravitreal Ranibizumab for Age-related Macular Degeneration
Age-related macular degeneration, a leading cause of blindness, is caused by an abnormal growth of the vessels beneath the retina.
- Trial name
- NCT00539734
- Testing
- ranibizumab
- Where
- Thailand
- Volunteers
- 25 people
- Sponsor
- Prince of Songkla University
Geographic Atrophy Secondary to Age-Related Macular Degeneration
A Study to Assess the Efficacy and Safety of RO7965032 in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
This study will assess the safety and efficacy of RO7965032 to address a significant unmet medical need in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD)
- Trial name
- NCT07851259
- Testing
- RO7965032
- Where
- 5 sites in United States
- Volunteers
- 321 people
- Sponsor
- Genentech, Inc.
Age-Related Macular Degeneration
Study of HUCNS-SC Subretinal Transplantation in Subjects With GA of AMD
A fellow eye controlled study of HUCNS-SC sub-retinal transplantation in subjects with bilateral GA AMD. All subjects will be assigned to HUCNS-SC transplantation.
- Trial name
- RADIANT (NCT02467634)
- Testing
- HuCNS-SC sub-retinal transplantation
- Where
- 12 sites in United States
- Volunteers
- 3 people
- Sponsor
- StemCells, Inc.
Neovascular Age-Related Macular Degeneration (nAMD), Neovascular (Wet) Age-related Macular Degeneration (AMD)
A Long-term Follow up Study of EXG102-031 in Patients With wAMD (Everest LTFU)
In neovascular (wet) age-related macular degeneration (nAMD), the macula, or the part of the eye that provides the clear, detailed central vision, is being affected by abnormal blood vessel growth and leakage.
- Trial name
- NCT06817343
- Testing
- Aflibercept (2.0 mg)
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Exegenesis Bio
Age-related Macular Degeneration, Low Vision
Automatic Self Transcending Meditation (ASTM) for Patients With Severe Age Related Macular Degeneration (AMD)
Age-related macular degeneration (AMD) is a condition affecting 20 to 25 million people worldwide. Symptoms of AMD includes difficulty in reading, recognizing faces and completing house work which may result in increased…
- Trial name
- NCT03104608
- Testing
- Automatic Self Transcending Meditation, Treatment as Usual
- Where
- Canada
- Volunteers
- 140 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Neovascular Age-Related Macular Degeneration
Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye
In this study researchers want to learn more about changes in visual acuity (clarity of vision) with a high dose treatment with Aflibercept (Eylea) in patients suffering from neovascular age-related macular degeneration (nAMD).
- Trial name
- PULSAR (NCT04423718)
- Testing
- Aflibercept High Dose VEGF Trap-Eye (BAY86-5321), Aflibercept VEGF Trap-Eye (Eylea, BAY86-5321)
- Where
- 235 sites in United States, Argentina and 25 more
- Volunteers
- 1,011 people
- Sponsor
- Bayer
Combretastatin A4 Phosphate, Age-related Macular Degeneration
Combretastatin A4 Phosphate in Patients With Neovascular Age-Related Macular Degeneration
The purpose of the study is assess safety, bioactivity, and maximal tolerated dose of repeated weekly intravenous infusion of combretastatin A-4 phosphate (CA4P) in patients with neovascular age-related macular degeneration
- Conditions
- Combretastatin A4 Phosphate, Age-related Macular Degeneration, AMD, CNV
- Trial name
- NCT01570790
- Testing
- Combretastatin A-4 phosphate
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Johns Hopkins University
"Wet" Age-Related Macular Degeneration
A Safety and Efficacy Study of Squalamine Lactate for Injection (MSI-1256F) for "Wet" Age-Related Macular Degeneration
Age-Related Macular Degeneration (AMD) is a degenerative eye disease of the retina that causes a progressive loss of central vision. AMD is the leading cause of blindness among adults age 50 or older in the Western world.
- Trial name
- NCT00139282
- Testing
- Squalamine Lactate
- Where
- 29 sites in United States
- Sponsor
- Genaera Corporation
Age Related Macular Degeneration
Effect of Oral Curcumin Supplementation in Dry Age-related Macular Degeneration (AMD) Patients
Nutrition plays an important role in preventing progression of dry age related macular degeneration (AMD), a disease of aging that leads to drusen deposits in the macula causing significant decrease in vision.
- Trial name
- NCT04590196
- Testing
- Longvida curcumin
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Illinois Chicago
Vitreous Injury, Retinal Detachment
Pars Plana Vitrecromy in Patients Aged 85 Years and Above
We reviewed the records of 120 consecutive patients (male and female), aged 85 years and above, who underwent pars plana vitrecromy in the Tel Aviv Medical Center during the years 01/01/2006 - 31/12/2013, and were followed by…
- Conditions
- Vitreous Injury, Retinal Detachment, Age Related Macular Degeneration
- Trial name
- PPV (NCT03222362)
- Testing
- Surgery
- Volunteers
- 120 people
- Sponsor
- Tel Aviv Medical Center
Wet Macular Degeneration
Non-Persistence/Non-Adherence (NP/NA) in Wet Age-related Macular Degeneration (wAMD) Patients in Germany
In the research study an observation of patients with wet age-related macular degeneration (wet AMD) will be performed. The term observational study indicates that the current course of therapy and the associated circumstances…
- Trial name
- NCT01448538
- Testing
- Anti-VEGF injections
- Where
- Germany
- Volunteers
- 480 people
- Sponsor
- Bayer
Choroidal Neovascularization, Age-related Macular Degeneration
A Study to Evaluate Ranibizumab in Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)
This is a Phase IIIb, single-masked, 1-year multicenter study of the safety and tolerability of intravitreally administered ranibizumab in subjects with active subfoveal CNV secondary to AMD.
- Trial name
- NCT00251459
- Testing
- rhuFab V2 (ranibizumab)
- Volunteers
- 5,000 people
- Sponsor
- Genentech, Inc.
Neovascular Age-related Macular Degeneration
Extension Study to Evaluate the Long-term Outcomes of Subjects in the CLS-AX CLS1002-101 Study
This is an open-label, non-interventional extension study of up to 12 weeks in duration in subjects completing Cohorts 2, 3, and 4 of the Parent study, CLS1002-101.
- Trial name
- NCT05131646
- Testing
- CLS-AX
- Where
- 7 sites in United States
- Volunteers
- 15 people
- Sponsor
- Clearside Biomedical, Inc.
Age-Related Macular Degeneration, Alzheiner's Disease
Study of Retinal Findings in People With Signs and Symptoms of Alzheimer s Disease Enrolled in 09-M-0198
Background: Alzheimer s disease affects the brain and causes memory and thinking problems in older people. Macular degeneration (MD) is an eye condition.
- Conditions
- Age-Related Macular Degeneration, Alzheiner's Disease, AMD
- Trial name
- NCT02226835
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- National Eye Institute (NEI)
Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema
Study of DS-7080a for the Treatment of Macular Degeneration
The purpose of this study is to test DS-7080a, a monoclonal antibody, as a new treatment for neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME).
- Trial name
- NCT02530918
- Testing
- DS-7080a, Ranibizumab
- Where
- 12 sites in United States
- Volunteers
- 56 people
- Sponsor
- Daiichi Sankyo
Geographic Atrophy, Age-Related Macular Degeneration
Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy
The purpose of this study is to assess long-term safety of avacincaptad pegol intravitreal administration for patients with geographic atrophy (GA) who completed Study ISEE2008 (GATHER2) through the Month 23 visit on study…
- Trial name
- NCT05536297
- Testing
- avacincaptad pegol
- Where
- 117 sites in United States, Argentina and 15 more
- Volunteers
- 278 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Retinal Disease, Corneal Disease
Tissue Studies of Human Eye Diseases
The purpose of this project is to diagnose and evaluate ocular and related tissues with various diseases such as conjunctival, corneal, uveal, vitreoretinal and optic nerve disorders, ocular degenerative, metabolic or genetic…
- Conditions
- Retinal Disease, Corneal Disease, Diabetic Retinopathy, Uveitis
- Trial name
- NCT00001310
- Where
- United States
- Volunteers
- 3,833 people
- Sponsor
- National Eye Institute (NEI)
Exudative Age-Related Macular Degeneration
Efficacy and Safety of Intravitreal Conbercept With Modified Treat-and-Extend Regimens in Exudative AMD
This is a prospective study. Data from patients diagnosed with nAMD who have never received related treatment were collected. Treatment was an intravitreal injection of 0.5 mg conbercept using modified "T\&E" treatment plans.
- Trial name
- IIT-A (NCT05539235)
- Testing
- different degrees of adjustment of the injection interval
- Where
- China
- Volunteers
- 60 people
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.